It seems, therefore, that HBV makes a substantial contribution to the overall liver disease load and associated high death rates. These findings lend urgency to the implementation of prevention programmes and to the development of treatment modalities for those already carrying the virus or with ongoing liver disease.
Hepatitis B control From the data described above, it is evident that, in the Middle East, the population group at greatest risk for HBV infection and its sequelae are children under 5 years of age. The risk factors for HBV transmission, particularly within family settings, cannot be easily modified. Consequently, hepatitis B vaccination has been integrated into the national Expanded Programme on Immunisation (EPI) in almost all Middle Eastern Countries (WHO 1995) . In Jordan, this was preceded by a demonstration project that elicited data supporting the feasibility of such a programme. This project was carried out over a five year period in a rural/urban population of 60000 people, among whom 3000 newborns a year were vaccinated against hepatitis B at 2, 3, and 6 months of age within the EPI programme. The project provided a vehicle both for training EPI staff and for formulating educational programmes for the recipients. The results showed that EPI information and education activities targeted toward families and health care workers in the vaccination areas led to a hepatitis B vaccine uptake of 98% in EPI recipients, compared with 68% in populations not exposed to these activities. This degree of immune coverage set the stage for the eventual expansion of the immunisation programme into the remainder of the country, and vaccinations of all newborns in Jordan started in July 1995.
Cost benefit studies in Jordan have shown that integration of postnatal hepatitis B vaccination into the national EPI programme would result in sevenfold savings in direct health care costs. Such a programme is expected to result in a 57% decrease in the HBV carrier rate in any given birth cohort. However, while a 60% decrease in mortality from HBV infection is also expected, this reduction will not become apparent until at least 20-30 years later, when the first vaccinated cohorts reach the age at which chronic liver disease is expected to present clinically. Thus, while disease loads may eventually be reduced significantly, a number of limiting factors mean that total eradication of HBV infection is not a realistic prospect in the near future. These limiting factors include poor vaccine acceptance by the target population, lack of prevention of perinatal infection in S3 S4 Toukan a postnatal immunisation programme, and a poor antibody response to the vaccine in some people. In addition, until sufficient generations of infants have been immunised, there will continue to be large numbers of HBV carriers and associated cases of liver disease. There is a clear need, therefore, for continued development of effective treatments for patients with chronic hepatitis B and for elimination of the virus in carriers. Discussion Gust: In the first of your cost-benefit analyses, you said that only about 10% of pregnant women were HBeAg positive, and that is where you would expect the failures in your immunisation programme to occur, and yet you predict that only about 69% of carriers will be prevented by perinatal immunisation strategies. Normally, one would expect 95% of babies born to HBeAg negative mothers to be protected, and some of the babies born to HBeAg positive mothers, so why are your predicted figures so low? Toukan: One has to take a worst case scenario when doing a cost-benefit analysis. If compliance is estimated to be around 85% and vaccine efficacy about the same, that gives an overall protection rate of about 70%. Hollinger: Does your vaccination course include an extra dose at 12 months, as well as the initial three doses at 2, 3, and 4 months? Toukan: No. There seems to be enough evidence that vaccination of infants at 2, 3, and 4 months is sufficiently immunogenic to allow protection for at least 10 years. In our demonstration projects, we gave the measles vaccine at 2, 3, and 9 months but, by the third injection, there was an uptake of only 60 or 70%. So delaying the third dose to increase immune levels over a longer period of time was done at the expense of compliance. Kew: When you calculated the risk of hepatocarcinoma in HBV carriers, HCV carriers and those with HBV and HCV together, did you calculate a relative risk for each? Toukan: No. We estimated the five year mortality by entering patients with viral induced cirrhosis into a five year observation period and calculating the death rate at the end of this time period. Hollinger: This is a very high five year death rate. Of course, it depends on the stage of their liver disease when they enter the study. There is a big difference in mortality between someone starting with mild chronic hepatitis and someone with cirrhosis or severe chronic active hepatitis, for example. Toukan: They were matched for liver disease stage before entering the five year follow up period.
